Psyence Biomedical Ltd.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Psyence Biomedical Ltd. is a biotechnology company specializing in the development of botanical, nature-derived psychedelic medicines primarily focused on mental health disorders within palliative care. The company’s core offerings include pharmaceutical-grade psilocybin and ibogaine products; these are developed as psychedelic Active Pharmaceutical Ingredients (APIs) and medicinal formulations intended for clinical use to treat conditions such as adjustment disorder, anxiety, depression, and substance use disorders. Psyence operates a vertically integrated biotechnology platform with in-house capabilities encompassing cultivation, manufacturing, and clinical development of these nature-derived psychedelic therapies. The company primarily targets oncology and palliative care patients, as well as broader mental health markets, with clinical operations and commercial partnerships spanning North America, the United Kingdom, and Africa. Founded in 2020 and headquartered in Canada, Psyence has recently intensified its strategic collaboration and ownership in PsyLabs, a Southern African supplier of GMP-grade psilocybin and ibogaine. In 2024 and 2025, Psyence made significant equity investments totaling $4 million in PsyLabs to secure an ethical, sustainable supply of high-potency psychedelic compounds. PsyLabs has achieved a major milestone by producing GMP-aligned ibogaine total alkaloid extract that meets food-grade safety standards for clinical and therapeutic applications. This supply chain integration supports Psyence’s advancing clinical programs, including a Phase IIb study of nature-derived psilocybin combined with psychotherapy for adjustment disorder in palliative care. Recent operational expansions include broadening patient eligibility criteria for clinical trials and activation of three clinical sites to accelerate patient enrollment. In terms of business developments, Psyence announced a new psilocybin longevity research initiative focusing on the effects of psilocybin on biological aging and healthspan markers. The company also completed the acquisition of Psyence Group’s stake, enhancing its vertical integration. Psyence maintains a strong cash position with no outstanding debt and has regained Nasdaq compliance following a reverse stock split. Their strategic focus is positioning Psyence in the projected $3.3 billion psychedelics market by 2031, emphasizing natural psychedelic therapies developed through robust scientific validation and sustainable practices. Psyence is recognized as a pioneer in advancing naturally derived psychedelic medicines through both clinical innovation and a controlled, ethical supply chain from cultivation to patient delivery.
Tredium Solutions Selected to Support Scripius' Pharmacy Benefits Platform
Psyence BioMed Announces U.S. Strategic Engagement Initiative Focused on GMP Ibogaine Research and Manufacturing
Pacific Bay Adopts Semi-Annual Reporting
Psyence BioMed Initiates Patient Dosing in Phase IIb Trial Evaluating NPX-5 for Adjustment Disorder
PBM Jumps On Trump Psychedelic Push, Ibogaine Supply Story
Psyence BioMed Positioned as World's only Licensed Pharmaceutical Grade Ibogaine Supplier at Source
Psyence BioMed Positioned as World's only Licensed Pharmaceutical Grade Ibogaine Supplier at Source
Psyence BioMed Welcomes U.S. Executive Action to Advance Research into Ibogaine
Aurwest Resources Announces Execution of Definitive Agreement on Weaver Lake Gold Project
Psyence BioMed Expands Australian Clinical Site Network to Five Sites, Advancing NPX-5–Supported Clinical Activities
Head-To-Head Comparison: XBiotech (NASDAQ:XBIT) and Psyence Biomedical (NASDAQ:PBM)
Corporate Update: Psyence BioMed Advances Vertically Integrated Pharmaceutical Platform Following PsyLabs Export Milestone
Psyence BioMed Announces Export of GMP-Manufactured Natural Psilocybin (NPX-5) to Australia for Ongoing Phase IIb Clinical Trial
Psyence BioMed Announces Exercise of Put Option by PsyLabs and Strategic Equity Investment
Psyence BioMed Announces Results of Annual and Special Meeting of Shareholders
Psyence BioMed Approves Put Option Agreement with PsyLabs to Secure Strategic Supply and Strengthen Commercialization Pathway
Psyence BioMed Announces Settlement of Shareholder Litigation
Psyence BioMed Announces Effective Date for 1-for-6.25 Reverse Stock Split
Psyence BioMed Announces Adjournment of Annual and Special Shareholder Meeting on January 22, 2026
Psyence BioMed Announces Postponement of Previously Announced Reverse Stock Split Effective Date